I am in no way opposed, to any upcoming capital raise, having a surplus of cash on hand is never a bad thing. And the miniscule dilution is of no consequence, they will still have under or close to 20 million outstanding shares.
That is a paltry sum, and will when positive news hits about possible licencing of Polystart, Phase 1 final data possibly showing extended disease recurrence, or initial news on first patients treated in Phase 2’s. They will be needing those shares to affect liquidity in the market.
Contrary to any misleading posts, Tapimmune has delivered on all milestones that they have initiated to date.
Anyone with any knowledge of the Bio Tech industry, is fully aware of the timelines to execution, Tapimmune has garnered, then executed on everything that they have set out to accomplish to date.
Tapimmune may finally be on the cusp of something special. Why would anyone at this point in time [especially those who have sat around for the past 13/15 years] sell now that they are so close to showing the fruition of their hard work.
It would be very irresponsible for long term holders, to sell now when there are so many upcoming catalyst’s.
This is it, 2018 will in all likelihood be the turning point for Tapimmune, positive or negative. They have multiple Phase 2 trials initiated, and by the end of 2018 we will have enough data on those trials to determine their long term success.
Polystart, may be a strong revenue stream in the future [per licencing]. And if by some act of God all of Tapimmune’s trials turn out to be negative, Polystart may be directed towards infectious disease, and it is not out of the question that they will be able to attract partners and/or a Government contract in that sector.
I myself am confident in the DoD, Mayo clinic, Keith Knutson, Edith Perez and Mr. Hoang, I have watched as Tapimmune has set the stage to finally, become successful. There Phase 1 trial data was stellar, and with the initiation of yet another peptide, which I believe is incorporated into the Phase 2 trials. I believe that the Phase 2 data is going to be positive, and may be enhanced by Polystart as well.
Tapimmune “has” executed everything that they have promised, and I for one support them for taking the additional time up front, to cross all their T’s and dot their I’s. Rather than try to rush for the sake of shareholders appeasement, and be subject to the FDA denying or delaying when Phase 2 data is submitted.
Anyone who is not excited about 2018/2019, in regard to Tapimmune’s platform, and its chances of success in some regard, does not understand the science moving forward.
Tapimmune has garnered, in the past 2 years albeit quietly, some strong partnerships, and once the final Phase 1, if positive will change the landscape for Tapimmune. And if the initial Phase 2’s are positive, then we all know that this stock [with such a low float, even at 20 million OS] will take off.
A company with substantial cash in bank, multiple ongoing trials, low debt, tiny share float, great partnerships, strong management, and possible life saving product [s] all add up to what may be a very successful company moving forward.
Do not be swayed, by listening to negative, unfounded allegations, against the company. There are those of us that truly do our DD many of who are regular posters on this board, who I am indebted for their invaluable contributions per the science.
I agree it has been a hard fought battle to date, and there were times that I myself have had reservations, as to Tapimmune’s ongoing success. But I personally, fully committed to holding my position through 2019.
And will state on record, that I believe in my personal DD in regards to
Tapimmune, and fully expect to be rewarded in the near term.
We will see.
To all positive contributors on this board, may all your families have a safe and 2018 Happy New Year…
The best is yet to come.
BLU
